Combination of Almonertinib and Concurrent Chemoradiotherapy in Unresectable Stage III NSCLC
Status:
Recruiting
Trial end date:
2023-06-02
Target enrollment:
Participant gender:
Summary
This is a Prospective, open, single arm study to evaluate the efficacy and safety of the
almonertinib combined with concurrent chemoradiotherapy in unresectable stage III NSCLC with
EGFR mutation